The antiserum was produced against synthesized peptide derived from human PEA-15 around the phosphorylation site of Ser116. AA range:81-130

Phospho-PEA-15 (S116) Polyclonal Antibody detects endogenous levels of PEA-15 protein only when phosphorylated at S116.The name of modified sites may be influenced by many factors, such as species (the modified site was not originally found in human samples) and the change of protein sequence (the previous protein sequence is incomplete, and the protein sequence may be prolonged with the development of protein sequencing technology). When naming, we will use the "numbers" in historical reference to keep the sites consistent with the reports. The antibody binds to the following modification sequence (lowercase letters are modification sites):QPsEE

PEA15

Astrocytic phosphoprotein PEA-15

PEA15 ;
Astrocytic phosphoprotein PEA-15 ;
15 kDa phosphoprotein enriched in astrocytes ;
Phosphoprotein enriched in diabetes ;
PED

phosphoprotein enriched in astrocytes 15(PEA15) Homo sapiens This gene encodes a death effector domain-containing protein that functions as a negative regulator of apoptosis. The encoded protein is an endogenous substrate for protein kinase C. This protein is also overexpressed in type 2 diabetes mellitus, where it may contribute to insulin resistance in glucose uptake. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jul 2014],

Function:Blocks Ras-mediated inhibition of integrin activation and modulates the ERK MAP kinase cascade. Inhibits RPS6KA3 activities by retaining it in the cytoplasm (By similarity). Inhibits both TNFRSF6- and TNFRSF1A-mediated CASP8 activity and apoptosis. Regulates glucose transport by controlling both the content of SLC2A1 glucose transporters on the plasma membrane and the insulin-dependent trafficking of SLC2A4 from the cell interior to the surface.,PTM:Phosphorylated by protein kinase C and calcium-calmodulin-dependent protein kinase. These phosphorylation events are modulated by neurotransmitters or hormones.,similarity:Contains 1 DED (death effector) domain.,subcellular location:Associated with microtubules.,subunit:Binds RPS6KA3, MAPK3 and MAPK1. Transient interaction with PLD1 and PLD2 (By similarity). Interacts with CASP8 and FADD.,tissue specificity:Ubiquitously expressed. Most abundant in tissues such as heart, brain, muscle and adipose tissue which utilize glucose as an energy source. Lower expression in glucose-producing tissues. Higher levels of expression are found in tissues from individuals with type 2 diabetes than in controls.,

Cytoplasm. Associated with microtubules.